Vivos (RDGL) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Vivos FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vivos's Free Cash Flow for the three months ended in Dec. 2023 was $-0.46 Mil. Vivos's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Vivos's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Vivos's current FCF Yield % is -2.79%.

The historical rank and industry rank for Vivos's FCF Margin % or its related term are showing as below:

RDGL' s FCF Margin % Range Over the Past 10 Years
Min: -32200 Med: -6465 Max: -3111.11
Current: -6465

During the past 13 years, the highest FCF Margin % of Vivos was -3111.11%. The lowest was -32200.00%. And the median was -6465.00%.

RDGL's FCF Margin % is ranked worse than
97.69% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: -7.275 vs RDGL: -6465.00

Vivos FCF Margin % Historical Data

The historical data trend for Vivos's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos FCF Margin % Chart

Vivos Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-8,370.00

-12,514.29

-6,426.67

-3,111.11

-6,465.00

Vivos Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-4,700.00	-4,900.00	-4,485.71	-3,171.43	-

Competitive Comparison of Vivos's FCF Margin %

For the Medical Devices subindustry, Vivos's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivos's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Vivos's FCF Margin % falls into.

Vivos FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Vivos's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1.293	/	0.02
	=	-6,465.00 %

Vivos's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.463	/	0
	=	%

Vivos FCF Margin % Related Terms

Thank you for viewing the detailed overview of Vivos's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivos (RDGL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

719 Jadwin Avenue, Richland, WA, USA, 99352

Website

https://www.radiogel.com

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.

Executives

Michael K Korenko	officer: INTERIM CEO AND PRESIDENT	6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack	officer: Interim CFO	114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle	10 percent owner	505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak	director	9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement	director	12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff	officer: Chief Financial Officer	206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust	10 percent owner	909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff	director, 10 percent owner, officer: CEO	719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford	director, 10 percent owner	6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell	director, 10 percent owner	6208 W OKANOGAN AVE, KENNEWICK WA 99336